Parallel Session 1 The Role of the Statistician in Post- Marketing, Including Surveillance Organizers –Harry Bushar (FDA-CDRH) –Greg Campbell (FDA-CDRH)

Slides:

Advertisements

Similar presentations

The Role of Statistics Post-Market Jay Herson, Ph.D. Johns Hopkins University Sept 29, 2006.

Advertisements

Drugs vs. Devices Jeng Mah & Gosford A Sawyerr Sept 16, 2005.

Non-randomized studies: Studies with historical controls and the use of Objective Performance Criteria (OPCs) Jeff Cerkvenik Statistics Manager Medtronic,

Delete these guides from slide master before printing or giving to the client 1 Bayesian Trial Design – Case studies Panelists Andrew Mugglin, Medtronic.

Parallel Session 9 Contemporary Challenges in Statistical Evaluation of Diagnostic Products Chairs:Gene Pennello (CDRH) Lakshmi Vishnuvajjala (CDRH) Stuart.

Postmarket Surveillance of Medical Device Adverse Events Hesha Jani Duggirala, PhD Epidemiology Branch Division of Postmarket Surveillance Office of Surveillance.

FDA/Industry Statistics Workshop 2005 Parallel Session 6: Vaccine Trials 10:10 am – 11:30 am, Sept. 16, 2005.

1 Other Issues for Statisticians in Medical Devices Gregory Campbell, Ph.D. Director, Division of Biostatistics Center for Devices and Radiological Health,

Discussion: Biostatistics in Public Policy

Challenges in Using a Formal Decision Analysis Approach to Medical Device Approval Larry Kessler, Sc.D. Director, Office of Science and Engineering Laboratories.

1 Danica Marinac – Dabic, M.D., Ph.D. Chief, Epidemiology Branch Office of Surveillance and Biometrics Center for Devices and Radiological Health Postmarket.

10/20/ The Pharmaceutical Industry and Their Influence on Pain Management in the ED J. David Haddox, DDS, MD VP, Risk Management & Health Policy.

Product Management & the FDA. Agenda/Scope What is different about managing products in a regulated industry? – Devices; Biologics; Pharma; Consumer goods;

IDEs in a New Device Space: An FDA View of Mitral John Laschinger, MD CDRH, ODE, DCD, SHDB Predictable And SuStainable Implementation Of National Registries.

Strengthening the Medical Device Clinical Trial Enterprise

@ PMCQ U October 19, Agenda l What is Advertising? l Pre-Launch Activities You Can Do l PAAB pre-NOC Meeting/Review policy.

CBER 510(k) Challenges and Strategies Susan Finneran Director of Clinical and Regulatory Affairs.

510k Submission Overview Myraqa, Inc. August 22, 2012.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

Over The Counter HIV Testing A Technology Whose Time has Come Freya Spielberg, MD MPH

FDA/CBER Role in Smallpox Vaccine Safety Bob Ball, MD, MPH, ScM Chief, Vaccine Safety Branch Office of Biostatistics and Epidemiology CBER, FDA January.

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

NATIONAL DEATH INDEX U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Center for Health Statistics.

Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.

Medical Device Revisions Case Study Phil Brown 20th September 2012.

Premarket Review Performance Goals Patricia B. Shrader BD November 18, 2004.

Medicines Transparency Alliance10/10/2015 Updates on Quality Presentations et al. John Allotey Manager, Business Developments LaGray Chemical Company Limited.

Concept Paper #3: Risk Assessment of Observational Data Session 1: Good Pharmacovigilance Practices Linda S. Hostelley on behalf of PhRMA.

Safe PCI for Women: View from the Pharmaceutical Industry Mark B. Effron, MD, FACC, FAHA, FCCP Medical Fellow Cardiovascular Medical Affairs Eli Lilly.

Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.

DHHS / FDA / CDRH 1 FDA Summary CardioSEAL® STARFlex™ Septal Occlusion System with Qwik Load NMT Medical P000049/S3.

1 TNF Blocker Safety: Lymphoma and Liver Failure Tim Coté MD MPH, Chief, Therapeutics & Blood Safety Branch, DE/OBE/CBER/FDA March 4, 2003.

Agenda for Session Compliance in Clinical Research

FDA ADVISORY COMMITTEES Mary A Foulkes, Ph.D. Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research, FDA FDA/Industry.

Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue, and Gene Therapies Web Seminar Series presents:

1 Estimating CDER Resources Devoted to Safety Theresa M. Mullin, Ph.D. Office of Planning, Office of Commissioner April 15, 2005 Presentation to: FDA Science.

1 Exotic Disease Response (EDR) Training Surveillance Processes – Overview.

Ethical issues with the regulatory use of gene expression data Benjamin S Wilfond MD Medical Genetics Branch National Human Genome Research Institute Department.

1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.

DHHS / FDA / CDRH 1 FDA Summary CardioSEAL® Septal Occlusion System with Qwik Load NMT Medical P

1 BETTER APPROACHES TO MONITORING MEDICAL PRODUCT SAFETY ARE NEEDED.

FDA Presentation P Computerized Thermal Imaging, Inc. CTI™ BCS 2100.

Clinical Trial Design and other Statistical Issues Mary A. Foulkes, Ph.D. Office of Biostatistics and Epidemiology Vaccines and Related Biological Products.

Intersecting roles CMS and FDA – implications for pharmaceutical and device industries Peter B. Bach, MD, MAPP Senior Adviser, Office of the Administrator.

Rachel Neubrander, PhD Division of Cardiovascular Devices

Evolving Importance of Post-Approval Studies

FDA Division of Cardiovascular Devices

Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S

Clinical Trials — A Closer Look

Surya Chitra, PhD MBA Director Biostatistics Endo Health Solutions

FDA Perspective on Cardiovascular Device Development

Balancing Pre and Postmarket Requirements Different Scenarios

Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.

Statistical Approaches to Support Device Innovation- FDA View

First-in-Man, First In The USA: What’s The Difference?

Medical Device Evaluation Division,

Update on the National Postmarket Surveillance System

Mortality and Antithrombotics: Focus on FAERS Repository

Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

FDA-CDRH in the Next Decade A Vision for Change

Erica Takai, PhD for Andrew Farb, M.D.

The Lifecycle of Pharmaceutical products

Combination products The paradigm shift

Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid- Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched,

Statistical Programming

Lessons Learned from the Mistakes of Others

Larry Kessler, Sc.D. Director

Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid- Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched,

Presentation transcript:

Parallel Session 1 The Role of the Statistician in Post- Marketing, Including Surveillance Organizers –Harry Bushar (FDA-CDRH) –Greg Campbell (FDA-CDRH) –Gosford Aki Sawyerr (Purdue-Pharma, L.P.) Moderators –Harry Bushar & Gosford Aki Sawyerr

Session Objectives Provide insight into the role of the statistician in FDA post-marketing activities, medical device trials and pharmaceutical post-marketing activities Challenge statisticians to be prepared to widen their sphere of influence from traditionally accepted roles

Agenda 8:20: Danica Marinac-Dabic, MD, PhD (Chief, Epidemiology Branch, OSB, CDRH) –CDRH Postmarket Transformation and the Role of the Statistician 8:40: Andy Mugglin, PhD (University of Minnesota) –Statisticians in Medical Device Post-Market Studies 9:00: Larry Gould, PhD (Merck Research Labs) –Statistical Considerations in Postmarketing Safety Evaluation 9:20: Discussant: Jay Herson, PhD (Johns Hopkins University)